Stifel Financial Corp Gamida Cell Ltd. Transaction History

Stifel Financial Corp

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$1.15 - $2.1 $2,673 - $4,882	-2,325 Reduced 16.14%	12,076 $15,000
Q3 2022 Nov 14, 2022	BUY	$1.53 - $3.39 $1,071 - $2,373	700 Added 5.11%	14,401 $23,000
Q2 2022 Aug 15, 2022	SELL	$1.73 - $4.29 $1,262 - $3,131	-730 Reduced 5.06%	13,701 $24,000
Q4 2021 Feb 14, 2022	BUY	$2.2 - $4.46 $31,748 - $64,362	14,431 New	14,431 $37,000

11.4M

235K

70.5K

Ticker GMDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,319,600
Market Cap $2.29M
Description
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials ...

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Stifel Financial Corp with notifications on news.